MedPath

The Effect of Spironolactone in Treatment of Essential Hypertensio

Phase 2
Conditions
Hypertension.
Essential (primary) hypertension
Registration Number
IRCT201502011525N6
Lead Sponsor
Shiraz University of Midical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Inclusion crireria: systolic blood pressure more than 135 mmhg; diastolic blood pressure more than 85 mmhg
Exclusion criteria: serum creatinine more than 2 mg/dl; serum potassium more than 5 meq/l; renal or other endocrine diseases; diabetes

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Systolic blood pressure. Timepoint: Before intervention and 1 month after intervention. Method of measurement: Ambulatory 24 hour blood pressure holter monitoring.;Diastolic blood pressure. Timepoint: Before intervention and 1 month after intervention. Method of measurement: Ambulatory 24 hour blood pressure holter monitoring.
Secondary Outcome Measures
NameTimeMethod
evel of serum potassium. Timepoint: Before Intervention and One Month After Intervention. Method of measurement: Biochemical Measurements on Blood Sample.
© Copyright 2025. All Rights Reserved by MedPath